1. 130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor. (December 2022) Authors: Sullivan, R.J.; Sharma, M.R.; Vaena, D.; Hamilton, E.; Izar, B.; Rasco, D.; Gainor, J.; D. Shepard, ; Papadopoulos, K.; Dumbrava, E.E.; Adewoye, H.H.; Ferre, P.J.; Ophir, E.; Patel, M.; Patnaik, A.; Chmielowski, B. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 158P Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant OVCA. (December 2022) Authors: Moroney, J.; Yeku, O.; Fleming, G.; Emens, L.A.; Vaena, D.; Dumbrava, E.E.; Rasco, D.; Sharma, M.R.; Papadopoulos, K.; Patnaik, A.; Sullivan, R.J.; Adewoye, H.H.; Ophir, E.; Cojocaru, G.; Ferre, P.J.; Izar, B.; Gaillard, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer. (December 2022) Authors: Yeku, O.; D. Shepard, ; Patel, M.; Fleming, G.; Vaena, D.; Rasco, D.; Chmielowski, B.; Sharma, M.R.; Hamilton, E.; Sullivan, R.J.; Papadopoulos, K.; Izar, B.; Cojocaru, G.; Ophir, E.; Ferre, P.J.; Dumbrava, E.E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 174P First-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: Preliminary monotherapy dose escalation data. (December 2022) Authors: Naing, A.; Wang, J.S.; Sharma, M.R.; Sommerhalder, D.; Gandhi, L.; Oh, D-Y.; Jiang, Y.; Michalski, J.; Lee, J.; Zhou, K.; Taylor, N.; Yan, L.; Roda, J.M.; Blum, L.; Ling, L.; Mikaelian, I.; Depaoli, A.M.; Hanes, V.; Kaplan, D.D.; Lieu, H.D. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of long‐term treatment with tumour necrosis factor‐α inhibitors on single‐dose ultraviolet‐induced changes in human skin. (15th November 2017) Authors: Kim, H.J.; Langenhan, J.L.; Robinson, E.S.; Privette, E.; Achtman, J.C.; Mitrani, R.A.; Zeidi, M.; Sharma, M.R.; Feng, R.; Nevas, J.L.; Calianno, C.; Okawa, J.; Taylor, L.; Pappas‐Taffer, L.; Werth, V.P. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1762 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effect of long‐term treatment with tumour necrosis factor‐α inhibitors on single‐dose ultraviolet‐induced changes in human skin. (1st December 2017) Authors: Kim, H.J.; Langenhan, J.L.; Robinson, E.S.; Privette, E.; Achtman, J.C.; Mitrani, R.A.; Zeidi, M.; Sharma, M.R.; Feng, R.; Nevas, J.L.; Calianno, C.; Okawa, J.; Taylor, L.; Pappas‐Taffer, L.; Werth, V.P. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1762 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗